(ACL)


NYSE - NYSE Delayed Price. Currency in USD
0.000.00 (0.00%)
Interactive chart
  • 1d
  • 5d
  • 1m
  • 6m
  • YTD
  • 1y
  • 2y
  • 5y
  • 10y
  • Max
1d
Open0.00
Prev Close0.00
Bid0.00 x
Ask0.00 x
Day's Range0.00 - 0.00
52wk Range
1y Target EstN/A
Market CapN/A
P/E Ratio (ttm)N/A
BetaN/A
Volume0
Avg Vol (3m)N/A
Dividend & YieldN/A (N/A)
Earnings DateN/A
Trade prices are not sourced from all markets
  • American City Business Journals11 months ago

    RTP's Envisia makes strides toward next-generation glaucoma treatment

    Research Triangle Park drug developer Envisia Therapeutics reported positive results for a possible next-generation glaucoma treatment. Glaucoma is the leading cause of preventable blindness globally. As with treatments across all diseases, compliance with the drug regiment contributes to poor performing treatments.

  • We're sorry this is all we were able to find about this topic.